SCHEMBL3820657

SCHEMBL3820657

Cc1ccc(S(=O)(=O)N2CCN(C(C)c3nc4ccc(Br)cc4c(=O)n3C)CC2)cc1

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 3/20 0.47
▸ LMNA P02545 3/20 0.47
▸ KDM4E B2RXH2 1/20 0.43
▸ THRB P10828 1/20 0.42
▸ HSD11B1 P28845 1/20 0.41
▸ PKM P14618 3/20 0.41
▸ METAP1 P53582 1/20 0.40
▸ ALDH1A1 P00352 2/20 0.40
▸ RXFP1 Q9HBX9 1/20 0.40
▸ POLB P06746 1/20 0.40
▸ HTT P42858 1/20 0.40
▸ GBA1 P04062 2/20 0.39
▸ NPSR1 Q6W5P4 1/20 0.39
▸ CACNA2D1 P54289 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ ABL1 P00519 1/20 0.38
▸ BCR P11274 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3817090 0.95 PKM (0.42) GAALMNAKDM4EPKMRXFP1
SCHEMBL3822489 0.92 PKM (0.47) GAALMNAHSD11B1PKMRXFP1
SCHEMBL3821683 0.91 GBA1 (0.44) LMNAKDM4EPKMRXFP1POLB
SCHEMBL3819087 0.90 CFTR (0.47) LMNAKDM4EHSD11B1PKMALDH1A1
SCHEMBL3820012 0.89 LMNA (0.48) GAALMNAKDM4EHSD11B1PKM
SCHEMBL15457091 0.89 LMNA (0.47) GAALMNAKDM4EHSD11B1PKM
SCHEMBL3824315 0.89 PKM (0.40) GAALMNAKDM4EPKMRXFP1
SCHEMBL13724345 0.89 LMNA (0.47) GAALMNAKDM4EHSD11B1PKM
SCHEMBL3825392 0.88 PKM (0.39) GAALMNAKDM4EPKMALDH1A1
SCHEMBL15457092 0.88 PKM (0.43) GAALMNAKDM4EPKMALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8642609-B2 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-02-04 — — US disclosed
US-8642609-B2 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-02-04 — — US disclosed
US-8642609-B2 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-02-04 — — US disclosed
EP-1646615-B1 PYRIMIDINE DERIVATIVES AS MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS VERTEX PHARMA (US) 2009-08-26 — — EP disclosed
US-20050059687-A1 Modulators of ATP-Binding Cassette transporters VERTEX PHARMACEUTICALS INCORPORATED 2005-03-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059687-A1 Modulators of ATP-Binding Cassette transporters CFTR, ABCB1, ABCC2 GAA 344/4885LMNA 3024/4885KDM4E 4337/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback